According to Zhitong Finance App, China Biopharmaceutical (01177.HK) announced that on July 13, 2026, the company will allocate and issue 102,300 new shares based on the conversion of mandatory convertible bonds due 2028 issued on March 20, 2024.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.